Advanced breast cancer remains incurable. For these patients, durable response and minimal toxicity are the main goals of current therapy. The antiestrogen tamoxifen has proved to be a significant advance in the treatment of breast cancer. Due to its partial estrogen activity, long term medication with tamoxifen has been found to cause endometrium proliferation wich can result in cancer in some patients. Reduction of estrogen production identified the aromatase inhibitors. Both steroidal substrate analog, type I inactivator, wich inactivate the enzyme and nonsteroidal competitive reversible, type II inhibitors, are now avaiable. Two new 3rd generation aromatase inactivators have recently completed phase III evaluation (anastrozole and letrozole) and we have some results investigating one of the new 3rd generation aromatase inhibitors (exemestane). The 3rd generation aromatase inhibitors and inactivators are better tolerated and more effective than each of our current standard 2nd line endocrin therapies. These agents are being directly compared with standard adjuvant medication, tamoxifen, or are being evaluated in different sequences.
|Translated title of the contribution||Aromatase inhibitors and inactivators in the treatment of advanced breast cancer|
|Number of pages||4|
|Publication status||Published - Dec 1 2000|
ASJC Scopus subject areas